

September 9, 2022



Todos Medical CEO Discusses Long COVID Economic Impact with Moneta Advisory Managing Partner Marc LoPresti

New York, NY, and Tel Aviv, ISRAEL, Sept. 09, 2022 (GLOBE NEWSWIRE) -- via [NewMediaWire](#) -- **Todos Medical, Ltd. (OTCQB: TOMDF)**, a comprehensive medical diagnostics and related solutions company, today released the Nasdaq MarketSite interview between Moneta Advisory Group's Managing Partner Marc LoPresti and CEO Gerald Commissiong, discussing the impact of Long COVID on the economy and how SARS-CoV-2 viral persistence is damaging population-level immunity leading to the [rise of viral outbreaks such as MonkeyPox](#). A link to the interview can be found at: <https://youtu.be/55pv1zKCDgl>.

Todos Medical, through its majority owned subsidiary 3CL Pharma, has commercialized Tollovid™, the 3CL protease inhibitor immune support dietary supplement with [recent data](#) in acute and Long COVID, with a [clinical proof of concept study planned](#) in Long COVID. 3CL is also developing the drug candidate Tollovir™, a combination 3CL protease inhibitor and CCR5 antagonist dual mechanism therapeutic currently preparing to enroll a new 46-patient treatment arm following a [successful Phase 2a clinical trial in hospitalized \(severe/critical\) COVID-19 patients](#) and [confirmatory biomarker data](#). Additionally, the Company has brought forth TolloTest™, a diagnostic assay measuring 3CL protease activity which correlates with SARS-CoV-2 replication as measured by PCR ct value, that has successfully completed [clinical proof of concept studies in hospitalized and outpatient settings](#). The Company believes TolloTest holds significant value in measuring viral activity in Long COVID.

Harvard economist David Cutler recently revised the estimated cost of Long COVID to the US economy to be \$3.7 trillion. Dr. Cutler notes on his [website](#): "Data suggest that 22-38% of people with COVID will have at least one symptom 12 weeks after initial onset, and 12-17% will have three or more symptoms. With 80.5 million confirmed COVID cases in the United States, this implies at least 9.6 million people with three or more symptoms of long COVID. The most common symptom of long COVID is fatigue, but every organ system has been implicated."

To learn more about the 3CL protease in SARS-CoV-2 replication, please visit www.3clpro.com. To purchase Tollovid please visit [Amazon](#) or www.MyTollovid.com.

About Todos Medical Ltd.

Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented [Todos Biochemical Infrared Analyses](#) (TBIA) is a proprietary cancer-screening technology using peripheral blood

analysis that examines cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company [Provista Diagnostics](#), Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing, [Long COVID Panel](#) analyses, and Provista's proprietary commercial-stage Videssa® breast cancer blood test. More information on Provista is available at www.provistadx.com.

Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

Todos formed the Israeli-based majority-owned joint venture 3CL Pharma, Ltd with NLC Pharma in March of 2022 to consolidate all of the intellectual property surrounding 3CL protease-based diagnostic testing and development of 3CL protease botanical and pharmaceutical inhibitors that target a fundamental reproductive mechanism of coronaviruses. 3CL Pharma, through Todos' brand, has commercialized the 3CL protease inhibitor immune support dietary supplement Tollovid™ in the United States, is developing the dual mechanism 3CL protease inhibitor and anti-cytokine therapeutic drug candidate Tollovir™, while also developing the 3CL protease diagnostic TolloTest™.

To purchase Tollovid please visit [Amazon](#) or www.MyTollovid.com. For more information, please visit <https://www.todosmedical.com/>.

Forward-looking Statements

Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final

product than anticipated; loss of market share and pressure on pricing resulting from the competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Todos Corporate Contact:

Daniel Hirsch CFO

Todos Medical

917-983-4229 x 104

Dan.h@todosmedical.com

Todos Press Contact:

Kyle Kappmeier

JConnelly

Vice President

973-975-7827

kkapmeier@jconnelly.com



Source: Todos Medical Ltd.